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      Background: Since January 1993 the Medtronic Open Pivot 
Mechanical Heart Valve has been implanted routinely in the 
aortic position at the authors’ institution. The study aim was 
to analyze, retrospectively, the 20-year clinical results of the 
prosthesis under a lowered anticoagulation regime. 
        Results: 90-day mortality was 0.7% (n=4, none valve-
related). Survival at 10-years was 86% and 73% at 20-years. 
Of the 153 total deaths, 46 were cardiac and 16 valve-related. 
Multivariable Cox-regression analysis selected age as a 
continuous variable (p<0.0001, HR 0.064/year), emergency 
operations (p=0.001, HR 0.93), hypertension (p=0.003, HR 
1.8), renal failure (p=0.004 HR 0.43), respiratory 
insufficiency (p=0.005, HR 0.55) and poor ventricular 
function (p=0.019, HR 0.02) as risk factors for death. Renal 
failure (p<0.0001) and hypertension (p=0.003) were 
considered risk factors for bleeding. Erratic INR (p=0.001) 
and vascular arteriosclerosis (p=0.019) were considered as a 
risk factor for thromboembolism.  
  
 
      Conclusions: This 22-year experience demonstrated 
excellent clinical outcomes with no structural valve failure. 
Odds ratio defined normotensive young patients as the 
lowest risk for adverse events. By contrast elderly age in 
combination with co-morbidities and instable 
anticoagulation yielded the worst long-term results. 
  
 
      Patients and Methods: Between January 1993 and December 
2012 a total of 1,056 valves was inserted in the aortic position 
into consecutive patients. Patients in sinus rhythm, with good 
left ventricular function and without major vascular pathology 
(n=552) were prospectively kept in a lower INR regime of 1.5-
2.5.  Mean age of the patients was 58+11.7 years. Preoperatively, 
38% of the patients were in NYHA class ≥III. Frequent co-
morbidities included: hypertension (n=228), vascular 
arteriosclerosis (n=157) and coronary disease (n=114). The 99% 
complete follow-up totaled 5,521 patient-years (range 24-267 
months). 
 
